靶向N6-甲基腺苷阅读蛋白YTHDF1的siRNA通过抑制EZH2-IL-6轴增强NASH-HCC抗肿瘤免疫
本研究探讨YTHDF1在非酒精性脂肪性肝炎相关肝细胞癌(NASH-HCC)中的作用。肝细胞特异性过表达Ythdf1的小鼠在NASH-HCC诱导饮食下发生肿瘤,单细胞RNA测序等显示Ythdf1诱导髓源性抑制细胞(MDSC)积聚并抑制细胞毒性CD8+ T细胞功能。机制上YTHDF1结合m6A修饰的EZH2 mRNA促进其翻译,EZH2增加IL-6表达和分泌。Ythdf1敲除或脂质纳米颗粒包裹的siRNA靶向Ythdf1可增强抗PD-1疗效。
要点
- YTHDF1在NASH-HCC肿瘤组织中过表达,肝特异性过表达驱动饮食诱导的NASH-HCC模型肿瘤发生。
- YTHDF1通过EZH2-IL-6轴招募并激活MDSC,抑制细胞毒性CD8+ T细胞功能。
- LNP包裹的siYthdf1与抗PD-1联用显著增强NASH-HCC同种移植瘤的抗PD-1疗效。
核心结论
- YTHDF1通过EZH2-IL-6信号促进NASH-HCC肿瘤发生,招募并激活MDSC导致细胞毒性CD8+ T细胞功能障碍。
- YTHDF1可能是提高NASH-HCC抗PD-1免疫治疗反应的新治疗靶点。
研究设计与样本
- 肝细胞特异性Ythdf1过表达小鼠接受NASH-HCC诱导饮食。
- 采用单细胞RNA测序、流式细胞术和免疫染色分析肿瘤浸润免疫细胞。
- 通过RNA测序、m6A测序、YTHDF1 RNA免疫沉淀测序、蛋白质组学和核糖体谱分析阐明YTHDF1的分子靶点。
- 在NASH-HCC模型中使用脂质纳米颗粒(LNP)包裹的小干扰RNA靶向Ythdf1。
主要发现
- NASH-HCC患者肿瘤组织中YTHDF1表达高于癌旁组织。
- 肝特异性Ythdf1过表达在自发性NASH-HCC饮食模型中驱动肿瘤发生。
- 单细胞RNA测序和流式细胞术显示Ythdf1诱导MDSC积聚并抑制细胞毒性CD8+ T细胞功能。
- NASH-HCC细胞中Ythdf1表达诱导IL-6分泌,介导MDSC招募和激活,导致CD8+ T细胞功能障碍。
- EZH2 mRNA被鉴定为YTHDF1的关键靶点,YTHDF1结合m6A修饰的EZH2 mRNA并促进EZH2翻译,EZH2增加IL-6表达和分泌。
临床怎么用
- Ythdf1敲除与抗PD-1治疗协同抑制NASH-HCC同种移植瘤生长。
- 使用LNP包裹的小干扰RNA靶向Ythdf1显著提高抗PD-1阻断在NASH-HCC同种移植瘤中的疗效。
- 作者认为YTHDF1可能是提高NASH-HCC抗PD-1免疫治疗反应的新治疗靶点,并为开发YTHDF1抑制剂治疗NASH-HCC提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: RNA N6-methyladenosine (m6A) reader protein YTHDF1 has been implicated in cancer; however, its role in hepatocellular carcinoma (HCC), especially in non-alcoholic steatohepatitis-associated HCC (NASH-HCC), remains unknown. Here, we investigated the functional role of YTHDF1 in NASH-HCC and its interplay with the tumor immune microenvironment. METHODS: Hepatocyte-specific Ythdf1-overexpressing mice were subjected to a NASH-HCC-inducing diet. Tumor-infiltrating immune cells were profiled with single-cell RNA-sequencing, flow cytometry, and immunostaining. The molecular target of YTHDF1 was elucidated with RNA-sequencing, m6A-sequencing, YTHDF1 RNA immunoprecipitation-sequencing, proteomics, and ribosome-profiling. Ythdf1 in NASH-HCC models was targeted by lipid nanoparticle (LNP)-encapsulated small-interfering Ythdf1. RESULTS: YTHDF1 is overexpressed in tumor tissues compared to adjacent peri-tumor tissues from patients with NASH-HCC. Liver-specific Ythdf1 overexpression drives tumorigenesis in dietary models of spontaneous NASH-HCC. Single-cell RNA-sequencing and flow cytometry revealed that Ythdf1 induced accumulation of myeloid-derived suppressor cells (MDSCs) and suppressed cytotoxic CD8+ T-cell function. Mechanistically, Ythdf1 expression in NASH-HCC cells induced the secretion of IL-6, which mediated MDSC recruitment and activation, leading to CD8+ T-cell dysfunction. EZH2 mRNA was identified as a key YTHDF1 target. YTHDF1 binds to m6A-modified EZH2 mRNA and promotes EZH2 translation. EZH2 in turn increased expression and secretion of IL-6. Ythdf1 knockout synergized with anti-PD-1 treatment to suppress tumor growth in NASH-HCC allografts. Furthermore, therapeutic targeting of Ythdf1 using LNP-encapsulated small-interfering RNA significantly increased the efficacy of anti-PD-1 blockade in NASH-HCC allografts. CONCLUSIONS: We identified that YTHDF1 promotes NASH-HCC tumorigenesis via EZH2-IL-6 signaling, which recruits and activates MDSCs to cause cytotoxic CD8+ T-cell dysfunction. YTHDF1 may be a novel therapeutic target to improve responses to anti-PD-1 immunotherapy in NASH-HCC. IMPACT AND IMPLICATIONS: YTHDF1, a N6-methyladenosine reader, is upregulated in patients with non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC); however, its role in modulating the tumor immune microenvironment in NASH-HCC remains unclear. Here, we show that Ythdf1 mediates immunosuppression in NASH-HCC and that targeting YTHDF1 in combination with immune checkpoint blockade elicits robust antitumor immune responses. Our findings suggest novel therapeutic targets for potentiating the efficacy of immune checkpoint blockade in NASH-HCC and provide the rationale for developing YTHDF1 inhibitors for the treatment of NASH-HCC.
引用
- Wang L, Zhu L, Liang C, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol. 2023. PMID: 37459919. doi:10.1016/j.jhep.2023.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。